Anti-CLDN antibody and pharmaceutical composition thereof and detection method therefor
Provided are an anti-CLDN18.2 antibody and a pharmaceutical composition thereof and a detection method therefor, wherein the heavy chain of the antibody is selected from any one of SEQ ID NOs: 1-7 or SEQ ID NOs: 15-30, and the light chain of the antibody is selected from any one of SEQ ID NOs: 8-14 or SEQ ID NOs: 31-46. The ability of the antibody to bind to cell lines and tumor tissue cells is more powerful than that of the existing antibody IMAB362, and the anti-tumor effect of the antibody is also more powerful than that of the existing antibody IMAB362.
1 . An anti-CLDN18.2 antibody or active fragment thereof which comprises a heavy chain and a light chain:
the heavy chain contains three CDRs, represented by HCDR1, HCDR2, and HCDR3, respectively;
the light chain contains three CDRs, represented by LCDR1, LCDR2, and LCDR3, respectively;
and the amino acid sequence of the anti-CLDN18.2 antibody or active fragment thereof comprises a combination of the CDRs:
HCDR1 comprising SEQ ID No: 47, HCDR2 comprising SEQ ID No: 48, and HCDR3 comprising SEQ ID No: 49; and
LCDR1 comprising SEQ ID No: 50, LCDR2 comprising SEQ ID No: 51, and LCDR3 comprising SEQ ID No: 52.
2 . The anti-CLDN18.2 antibody or active fragment thereof according to claim 1 , wherein the heavy chain of the antibody comprises SEQ ID No: 7; or the light chain of the antibody comprises SEQ ID No: 14.
3 . The anti-CLDN18.2 antibody or active fragment thereof according to claim 1 , wherein the heavy chain of the antibody comprises SEQ ID No: 7 and the light chain of the antibody comprises SEQ ID No: 14.
4 . A polynucleotide encoding the antibody or active fragment thereof according to claim 1 .
5 . A pharmaceutical composition comprising the antibody or active fragment thereof according to claim 1 .
6 . A method of detecting the presence of CLDN18.2 in a biological sample, which comprises:
a step of administering the antibody or active fragment thereof according to claim 1 to a biological sample, wherein the antibody has a detectable label;
and a step of detecting whether the detectable label is present or detecting the content of the detectable label.
7 . A method of treating CLDN18.2-expressing tumors, which comprises a step of administering a therapeutically effective amount of the antibody or active fragment thereof according to claim 1 to a subject in need thereof.